AKT1 and gastric cancer: It emerged that CRAL could function as a ceRNA for endogenous miR-505, thereby upregulating expression of cylindromatosis (CYLD), which, in turn, suppressed AKT activation and enhanced the sensitivity of gastric cancer cells to cisplatin via the miR-505/CYLD/AKT axis.